232 related articles for article (PubMed ID: 27984271)
1. Effects of Colloidal Oatmeal Lotion on Symptoms of Dermatologic Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors.
Ke YT; Kuo CC
Adv Skin Wound Care; 2017 Jan; 30(1):27-34. PubMed ID: 27984271
[TBL] [Abstract][Full Text] [Related]
2. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
Wagner LI; Berg SR; Gandhi M; Hlubocky FJ; Webster K; Aneja M; Cella D; Lacouture ME
Support Care Cancer; 2013 Apr; 21(4):1033-41. PubMed ID: 23128934
[TBL] [Abstract][Full Text] [Related]
3. A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors.
Wong SF; Lindgren A; Mummaneni M; Byun T; Vasko C; Arenos R; Alexson E; Osann K
J Support Oncol; 2010; 8(5):202-8. PubMed ID: 21086877
[TBL] [Abstract][Full Text] [Related]
4. Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors.
Boucher J; Olson L; Piperdi B
Clin J Oncol Nurs; 2011 Oct; 15(5):501-8. PubMed ID: 21951736
[TBL] [Abstract][Full Text] [Related]
5. Clinical management of EGFRI dermatologic toxicities: US perspective.
Lacouture ME; Cotliar J; Mitchell EP
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):17-21. PubMed ID: 18154214
[TBL] [Abstract][Full Text] [Related]
6. Clinical management of EGFRI dermatologic toxicities: the Japanese perspective.
Yamazaki N; Muro K
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):27-8. PubMed ID: 18159648
[TBL] [Abstract][Full Text] [Related]
7. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
Tan EH; Chan A
Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
[TBL] [Abstract][Full Text] [Related]
8. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
Lacouture ME; Maitland ML; Segaert S; Setser A; Baran R; Fox LP; Epstein JB; Barasch A; Einhorn L; Wagner L; West DP; Rapoport BL; Kris MG; Basch E; Eaby B; Kurtin S; Olsen EA; Chen A; Dancey JE; Trotti A
Support Care Cancer; 2010 Apr; 18(4):509-22. PubMed ID: 20145956
[TBL] [Abstract][Full Text] [Related]
9. Xerosis and pruritus as major EGFRI-associated adverse events.
Clabbers JMK; Boers-Doets CB; Gelderblom H; Stijnen T; Lacouture ME; van der Hoeven KJM; Kaptein AA
Support Care Cancer; 2016 Feb; 24(2):513-521. PubMed ID: 26111953
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
[TBL] [Abstract][Full Text] [Related]
11. Clinical management of EGFRI-associated dermatologic toxicities: pharmacy perspective.
Iacovelli L
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):31-3. PubMed ID: 18154216
[TBL] [Abstract][Full Text] [Related]
12. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.
Lacouture ME; Anadkat MJ; Bensadoun RJ; Bryce J; Chan A; Epstein JB; Eaby-Sandy B; Murphy BA;
Support Care Cancer; 2011 Aug; 19(8):1079-95. PubMed ID: 21630130
[TBL] [Abstract][Full Text] [Related]
13. Clinical management of EGFRI dermatologic toxicities: the European perspective.
Segaert S; Van Cutsem E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):22-6. PubMed ID: 18159647
[TBL] [Abstract][Full Text] [Related]
14. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
15. Managing skin toxicities related to panitumumab.
Bergman H; Walton T; Del Bel R; Seki JT; Rafii A; Xu W; Koren G; Shear N; Krzyzanowska MK; Howell D; Liu G
J Am Acad Dermatol; 2014 Oct; 71(4):754-9. PubMed ID: 25085331
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
17. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
Amitay-Laish I; David M; Stemmer SM
Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
[TBL] [Abstract][Full Text] [Related]
18. ARTICLE: Colloidal Oatmeal Part II: Atopic Dermatitis in Special Populations and Clinical Efficacy and Tolerance Beyond Eczema.
Allais B; Friedman A
J Drugs Dermatol; 2020 Oct; 19(10):s8-s11. PubMed ID: 33026769
[TBL] [Abstract][Full Text] [Related]
19. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors.
Peng Y; Li Q; Zhang J; Shen W; Zhang X; Sun C; Cui H
Biosci Trends; 2019 Jan; 12(6):537-552. PubMed ID: 30555112
[TBL] [Abstract][Full Text] [Related]
20. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]